CoChat
Sign Up
Cited by 215Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients

Schatzberg, Alan F., Kremer, Charlotte, Rodrigues, Heidi E., Murphy, Greer M.·2002·The American Journal of Geriatric Psychiatry
DOI 10.1097/00019442-200209000-00007
Open this paper in CoChat — free account

Abstract

Objective Authors studied the efficacy and tolerability of mirtazapine and paroxetine in elderly patients with major depression during an acute phase (8 weeks) and an extension phase (16 weeks). Methods Patients with major depression and without dementia, at least 65 years old, were eligible; they were randomized to mirtazapine or paroxetine once daily, with doses increasing over 42 days. Efficacy was assessed with the Ham-D and Clinical Global Impressions Scale, and tolerability was assessed from adverse events. Results Of 255 patients randomized, 126 on mirtazapine and 120 on paroxetine were included in the efficacy analysis. Differences favoring mirtazapine were observed for the mean change from baseline in Ham-D-17 score. Other significant differences were in the proportion of patients classified as responders (50% decrease from baseline Ham-D-17 scores) at Day 14 and in remission (Ham-D-17 score of 7 or less) at Day 42. The median time to response was 26 days in the mirtazapine group and 40 days in the paroxetine group. The mirtazapine group also showed more reduction in Ham-D Factor I (Anxiety/Somatization) and Factor VI (Sleep Disturbance) scores. Efficacy of both drugs was maintained during the extension phase. Patients on paroxetine were more likely to discontinue therapy in the acute phase because of adverse events. Conclusion During the first weeks of treatment, antidepressant effects were more pronounced in the mirtazapine group, suggesting that mirtazapine has an…

Overview

Integrity signals

Registry

Crossref · 10.1097/00019442-200209000-00007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HAMD sleep scores were poorer with paroxetine (20-40mg) than mirtazapine (15-45mg).

    “(Schatzberg et al., 2002) demonstrated that HAMD sleep scores were poorer with paroxetine (20-40mg) than mirtazapine (15-45mg).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Schatzberg et al., 2002

  • Earlier analyses comparing mirtazapine to other antidepressants indicated better HAMD sleep scores than with paroxetine.

    “Earlier analyses comparing mirtazapine to other antidepressants, indicated less nocturnal disturbance and better sleep efficiency than with fluoxetine (Winokur et al., 2003) or paroxetine (Ridout et al., 2003), and better HAMD sleep scores than with paroxetine (Schatzberg et al., 2002) or venlafaxine (Guelfi et al., 2001).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Schatzberg et al., 2002

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. Draper, 2000, The effectiveness of the treatment of depression in the physically ill elderly, Aging and Mental Health, 4, 9, 10.1080/13607860055928 · DOI
  2. Salzman, 1999, Practical considerations for the treatment of depression in elderly and very elderly long-term care patients, J Clin Psychiatry, 60, 30
  3. Montgomery, 1998, Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients, Int Clin Psychopharmacol, 13, S49, 10.1097/00004850-199809005-00010 · DOI
  4. Reynolds, 1999, Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized, controlled trial in patients older than 59 years, JAMA, 281, 39, 10.1001/jama.281.1.39 · DOI · Paper page
  5. Small, 1998, Treatment of geriatric depression, Depress Anxiety, 8, 32, 10.1002/(SICI)1520-6394(1998)8:1+<32::AID-DA6>3.0.CO;2-J · DOI
  6. De Boer, 1996, The pharmacologic profile of mirtazapine, J Clin Psychiatry, 57, 19
  7. De Boer, 1994, The α2-adrenoreceptor antagonist Org 3770 enhances serotonin transmission in vivo, Eur J Pharmacol, 253, R5, 10.1016/0014-2999(94)90778-1 · DOI
  8. Stahl, 1997, Metaanalysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression, Acta Psychiatr Scand Suppl, 391, 22, 10.1111/j.1600-0447.1997.tb05955.x · DOI
  9. Holm, 1999, Mirtazapine: a review of its use in major depression, Drugs, 57, 607, 10.2165/00003495-199957040-00010 · DOI
  10. Fawcett, 1998, A metaanalysis of eight randomized, double-blind controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety, J Clin Psychiatry, 59, 123, 10.4088/JCP.v59n0306 · DOI
  11. Timmer, 2000, Clinical pharmacokinetics of mirtazapine, Clin Pharmacokinet, 38, 461, 10.2165/00003088-200038060-00001 · DOI
  12. Delbressine, 1997, The clinical relevance of preclinical data: mirtazapine, a model compound, J Clin Psychopharmacol, 17, 29S, 10.1097/00004714-199704001-00004 · DOI
  13. Kat MG, Helsdingen JTH, Boumans AAJ: Efficacy and tolerability of mirtazapine used by elderly depressed patients in The Netherlands. Presented at the 11th European College of Neuropsychopharmacology Meeting; Oct 31-Nov 4, 1998; Paris, France · DOI
  14. Høyberg, 1996, A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients, Acta Psychiatr Scand, 93, 184, 10.1111/j.1600-0447.1996.tb10629.x · DOI
  15. Halikas, 1995, Org 3770 (mirtazapine) versus trazodone: a placebo-controlled trial in depressed elderly patients, Hum Psychopharmacol, 10, S125, 10.1002/hup.470100807 · DOI
  16. Crum, 1993, Population-based norms for the Mini-Mental State Exam by age and educational level, JAMA, 269, 2386, 10.1001/jama.1993.03500180078038 · DOI
  17. Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  18. Thase, 1997, When at first you don't succeed: sequential strategies for antidepressant nonresponders, J Clin Psychiatry, 58, 23
  19. Wheatley, 1998, Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate-to-severe major depressive disorder, J Clin Psychiatry, 59, 306, 10.4088/JCP.v59n0606 · DOI
  20. Leinonen, 1999, Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder, Int Clin Psychopharmacol, 14, 329, 10.1097/00004850-199911000-00002 · DOI · Paper page
  21. Benkert, 2000, Mirtazapine compared to paroxetine in major depression, J Clin Psychiatry, 61, 656, 10.4088/JCP.v61n0911 · DOI
  22. Nutt, 1999, Care of depressed patients with anxiety symptoms, J Clin Psychiatry, 60, 23
  23. Mulsant, 1999, A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression:6–week outcome, J Clin Psychiatry, 60, 16
  24. Bondareff, 2000, Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life, Am J Psychiatry, 157, 729, 10.1176/appi.ajp.157.5.729 · DOI
  25. Schone, 1993, A double-blind study of paroxetine compared with fluoxetine in patients with major depression, J Clin Psychopharmacol, 13, 34S
  26. Finkel, 1999, Comparative efficacy of sertraline and fluoxetine in patients age 70 or over with major depression, Am J Geriatr Psychiatry, 7, 221, 10.1097/00019442-199908000-00006 · DOI
  27. Mulsant, 1998, Treatment-resistant depression in late life, J Geriatr Psychiatry Neurol, 11, 186, 10.1177/089198879901100404 · DOI
  28. Finkel, 1999, Comparative efficacy and safety of sertraline versus nortriptyline for major depression in patients 70 and older, Int Psychogeriatr, 11, 85, 10.1017/S104161029900561X · DOI
  29. Mulsant, 2001, A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients, Am J Geriatr Psychiatry, 9, 406, 10.1097/00019442-200111000-00009 · DOI
  30. Lundmark, 1989, Paroxetine: pharmacokinetic and antidepressant effect in the elderly, Acta Psychiatr Scand Suppl, 350, 76, 10.1111/j.1600-0447.1989.tb07177.x · DOI
  31. Katona, 1998, A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia, Int J Geriatr Psychiatry, 2, 100, 10.1002/(SICI)1099-1166(199802)13:2<100::AID-GPS738>3.0.CO;2-J · DOI

Cited by

Sorted by citations

Metadata

Authors
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., & Murphy, G. M.
Affiliations
  • Stanford Medicine (US)
  • Seton Hall Preparatory School (US)
Corresponding author
Schatzberg, Alan F.
ORCID
Schatzberg, Alan F.
Venue
The American Journal of Geriatric Psychiatry
Publisher
Elsevier BV
Published
2002-09
Volume
10
Issue
5
Pages
541-550
ISSN
1064-7481 (ISSN-L)
DOI
10.1097/00019442-200209000-00007
OpenAlex
W2005597128
Cited by
215
References
3
Citations by year
2026: 2 · 2025: 5 · 2024: 12 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 15 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 10 · 2013: 10 · 2012: 13
FWCI
9.12
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • American Journal of Geriatric Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
mirtazapine, paroxetine, major depressive disorder, elderly patients, antidepressant efficacy, tolerability, adverse events, onset of action, remission, time to response, sleep disorders, anxiety, somatization, treatment discontinuation
MeSH terms
Mirtazapine, Aged, Analysis of Variance, Antidepressive Agents, Tricyclic, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Mianserin, Psychiatric Status Rating Scales, Time Factors, Paroxetine, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review